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Background: Asphyxia is the most common cause of brain damage in newborns.
Substantial evidence indicates that leukocyte recruitment in the cerebral vasculature
during asphyxia contributes to this damage. We tested the hypothesis that superoxide
radical (O
·
2) promotes an acute post-asphyxial inflammatory response and blood-brain
barrier (BBB) breakdown. We investigated the effects of removing O
·
2 by superoxide
dismutase (SOD) or C3, the cell-permeable SOD mimetic, in protecting against
asphyxia-related leukocyte recruitment. We also tested the hypothesis that xanthine
oxidase activity is one source of this radical.
Methods: Anesthetized piglets were tracheostomized, ventilated, and equipped with
closed cranial windows for the assessment of post-asphyxial rhodamine 6G-labeled
leukocyte-endothelial adherence and microvascular permeability to sodium fluorescein
in cortical venules. Asphyxia was induced by discontinuing ventilation. SOD and C3
were administered by cortical superfusion. The xanthine oxidase inhibitor oxypurinol was
administered intravenously.
Results: Leukocyte-venular adherence significantly increased during the initial 2 h
of post-asphyxial reperfusion. BBB permeability was also elevated relative to non-
asphyxial controls. Inhibition of O
·
2 production by oxypurinol, or elimination of O
·
2
by SOD or C3, significantly reduced rhodamine 6G-labeled leukocyte-endothelial
adherence and improved BBB integrity, as measured by sodium fluorescein leak from
cerebral microvessels.
Ruden et al. Superoxide-Lowering Therapies in Asphyxial Piglets
Conclusion: Using three different strategies to either prevent formation or enhance
elimination of O
·
2 during the post-asphyxial period, we saw both reduced leukocyte
adherence and preserved BBB function with treatment. These findings suggest that
agents which lower O
·
2 in brain may be attractive new therapeutic interventions for the
protection of the neonatal brain following asphyxia.
Keywords: asphyxia, carboxyfullerene, endothelium, inflammation, leukocytes, oxypurinol, superoxide, xanthine
oxidase
INTRODUCTION
Asphyxia is a relatively common source of neonatal brain
damage (1), affecting ∼2 in every 1,000 births (2). The
hypoxic ischemia resulting from this oxygen deprivation can
produce long-term sequelae, including intellectual disability
and neurologic deficits, and nearly a quarter of neonatal
deaths worldwide are attributable to birth asphyxia (2). A
dominant response to ischemia is inflammation (2, 3), resulting
from the accumulation of circulating leukocytes in the cerebral
microvasculature and their subsequent extravasation into brain
parenchyma (4–7). The mechanisms promoting the early
increase in leukocyte-endothelial interactions in the cerebral
circulation await further elucidation, but probable causes include
the elaboration of cytokines and chemokines (8, 9), and other
proinflammatory mediators (10). There is also consensus that
reactive oxygen species (ROS), formed during reperfusion
following transient ischemia, including in the neonatal brain, also
modulate inflammation (11–13).
ROS are generated in multiple compartments within
a cell and are produced by many sources, including
mitochondria, peroxisomal lipid metabolism, NADPH oxidases,
cyclooxygenase, and xanthine oxidase (14–16). Increased
levels of ROS are involved in the pathophysiology of many
neurodegenerative diseases, stroke, aging, and birth asphyxia
(13, 17–20). In vitro, O
·
2 is increased in neurons (21) and cerebral
endothelial cells (22) in response to anoxia-reoxygenation stimuli
that simulate ischemia-reperfusion. Activated leukocytes can
form copious amounts of O
·
2 from NADPH oxidase during their
respiratory burst (23). Xanthine oxidase and cyclooxygenase are
two enzymatic sources of O
·
2, in addition to formation of the
radical in the electron transport chain of mitochondria (23, 24).
Considerable evidence implicates ROS in playing a causal role
in ischemic brain damage (12, 23, 25). A burst of O
·
2 during
reoxygenation has been suggested to cause direct cellular damage
to macromolecules and initiate cellular signaling pathways
involved in cell survival and death, resulting in apoptosis in
ischemic lesions. The neonatal brain is believed to be especially
vulnerable to free radical damage, due in part to its low amount
of antioxidants (1).
Although a number of therapies are under consideration for
treating moderate to severe neonatal asphyxia (2, 26), therapeutic
hypothermia currently remains the standard treatment, despite
evidence showing that the long-range neuroprotective benefits
of hypothermia treatment are modest (1). A new potential
treatment for neonatal asphyxia is C3, a small, cell-permeable
C60 fullerene compound with SOD mimetic properties:
e,e,e tris malonic acid (e,e,e-C60(C(COOH2))3). Due to its
arrangement of malonic acid groups, C3 is amphiphilic and cell-
permeable, and can catalytically remove O
·
2 (27). C3 protected
against ischemia-mediated release of the intracellular enzyme
lactate dehydrogenase in mouse retinal endothelial cells (28).
Additionally, C3 improved motor function and protected against
striatal injury in parkinsonian non-human primates, a model
known to involve inflammation (29). C3 has proven to be
neuroprotective in other injury models (30, 31) and to improve
cognitive function and survival in a murine model of aging (19).
In contrast to these cytoprotective effects, the effects of C3 on
inflammatory endpoints are unknown.
In the present study, we utilized SOD, C3, and the xanthine
oxidase inhibitor oxypurinol to examine the involvement of O
·
2 in
mediating leukocyte adherence to post-capillary cerebral venules
and BBB permeability changes in response to asphyxia. We
tested whether O
·
2 is produced in response to asphyxia, whether
xanthine oxidase is a source of this radical, and whether the
inflammatory response caused by asphyxia can be prevented by
removing O
·
2 by SOD or C3 administration, or by preventing the
formation of this radical.
METHODS
Ethical Approval
Washington University Institutional Animal Care and Use
Committee approved the experiments, which were consistent
with Public Health Service guidelines. All experiments were
conducted in compliance with the ARRIVE guidelines.
Animals
Experiments were performed on piglets that were 1–4 days of
age, 1.5–3.0 kg, and of mixed sex. Animals were randomized
into control, asphyxia, and asphyxia plus treatment groups.
Fluorescently-labeled leukocytes within pial microvessels on
the cortical surface of the piglet brain were imaged through
a closed cranial window. Rhodamine 6G was used to label
circulating leukocytes in situ (loading dose: 2 ml/kg of a
filtered 0.06 mg/ml solution, 20min prior to the first baseline
measurement; Sigma Chemical, St. Louis, MO), as previously
described (32–34). To enhance leukocyte labeling, additional
rhodamine was infused (800 µl/min/kg for 30–45 s) before
each imaging time point. Real-time, high-resolution images
of rhodamine-labeled leukocytes were recorded to videotape
(Super VHS) using an epifluorescence microscope (Olympus,
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Lake Success, NY) with a rhodamine-specific optical filter (535
nm/35 nm excitation, 565 nm dichroic, 610 nm/75 nm emission),
10× immersion lens (0.4 numerical aperture, 3.1mm working
distance; Olympus), and a C-2400 Newvicon tube camera
(Hamamatsu, Bridgewater, NJ).
Piglets were anesthetized with ketamine hydrochloride (20
mg/kg IM), tracheostomized, and ventilated with room air
and oxygen. End-tidal CO2 and transcutaneous O2 were
monitored continuously using a capnometer and forepaw
sensor, respectively. Anesthesia was maintained by ventilating
with isoflurane (1.0–1.5%) while paralysis was sustained using
pancuronium (0.25 mg/kg/h IV). A cannula was placed in one
femoral vein for administration of the paralytic agent and 5%
dextrose in 0.45% normal saline (6 ml/kg/h) to maintain fluid
status. Both femoral arteries were cannulated to record arterial
blood pressure and to measure blood gases, blood glucose, and
pH. Body temperature was maintained at 38–39◦C using a
thermoregulated heating pad. A closed Plexiglass cranial window
was mounted over the right parietal cortex just posterior to the
coronal suture and was slowly filled with artificial cerebral spinal
fluid (aCSF) buffer after mounting. Through circumferentially
placed ports on the window, intracranial pressure wasmonitored.
Asphyxia
After the cranial window was placed, the animal and surgical
site were allowed to stabilize for 30min, and then two baseline
video recordings were obtained 30min apart. Asphyxia was
then induced by discontinuing ventilation for 9min, resulting
in severe hypoxia, hypercapnia, hypotension, bradycardia, and
acidosis. These conditions resolved in the vast majority of
animals within 30min after resuming ventilation without the use
of resuscitation (32–34). A very small minority of animals died in
response to asphyxia. Arterial blood pressure was recorded and
blood gases, blood glucose, and pH were measured at baseline
and at 1 and 2 h of reperfusion.
In this study, C3 and SOD were administered by cortical
superfusion through the cranial window, whereas oxypurinol was
given intravenously. To determine whether window superfusion
of aCSF affected leukocyte adhesion differently than allowing
aCSF to remain static, we established two asphyxia groups. In
one, the cranial window was filled with aCSF buffer before
baseline measurements were initiated, and the fluid beneath the
windows remained undisturbed. In another, the window was
superfused at 50 µl/min with aCSF beginning 30min before
asphyxia and continuing throughout the 2 h of reperfusion. The
leukocyte adherence and vascular permeability data from these
2 asphyxia groups were statistically analyzed and graphed in
comparison to their respective drug-treated groups, and the
mean arterial blood pressure, blood glucose, arterial pH, arterial
partial pressure of CO2, and arterial partial pressure of O2 data
from these 2 asphyxia groups were also statistically analyzed in
comparison to their respective drug-treated groups. In a similar
fashion, the cranial windows of 2 separate non-asphyxial control
groups were either superfused with aCSF or allowed to remain
static once filled, and were imaged over the same time period. No
difference in the magnitude of leukocyte adherence or vascular
permeability to fluorescein was noted between these 2 control
groups, so the data from the 2 non-asphyxial control groups were
merged into a single control group.
Drug Administration
Oxypurinol (5 mg/kg or 50 mg/kg) was dispensed as an
intravenous bolus, 30min before asphyxia. SOD (1,000 U/ml;
Oxis International, Portland, OR) or C3 [pH 7.0, 300µM;
synthesized as described previously (27, 29, 35)] were dissolved
in aCSF and administered by cortical superfusion (50 µl/min)
through the cranial window starting 30min before asphyxia and
continuing throughout the 2 h of post-asphyxial reperfusion.
Quantification of Intravascular
Leukocyte Dynamics
Leukocytes adhering to the endothelium of pial venules
were quantified during off-line videotape playback on a high
resolution monitor by an observer blind to experimental
condition using OPTIMAS image analysis software (BioScan,
Inc., Edmonds, WA). Initially, the two-dimensional surface
areas of 2 separate contiguous groups of 2 or more small (20–
80µm) post-capillary venules and their primary branches were
determined. Then the three-dimensional area of the venous
network was calculated by multiplying the determined area by pi.
Leukocytes were manually counted and designated as adherent
if they remained stationary within the venule for longer than
10 s. The number of leukocytes per millimeter vessel surface
was calculated by dividing the raw leukocyte number by the
3-dimensional area of the venular network.
BBB Permeability
Intravenous sodium fluorescein (MW = 376) was used to assess
the effects of different drug treatments on the increase in BBB
permeability induced by asphyxia, as described in detail in earlier
publications (32, 34). Briefly, after 2 h of reperfusion, 1 ml/kg
of a 0.04% solution of sodium fluorescein was administered
intravenously over 1 min.
Sodium fluorescein’s extravascular presence was quantified
using the OPTIMAS image analysis software with a linear
intensity (0–255) scale. Video recordings were obtained just prior
to the fluorescein injection and during the initial minute after its
administration to obtain background andmaximum/peak optical
density (OD) values, respectively, and then again 20minutes
thereafter. The OD was measured oﬄine in an experimental
group-blindedmanner at 3 separate extravascular locations along
a large portion of the length of 2 different venules chosen
from the video field vascular network (total of 6 perivenular
locations). Changes in OD were normalized along a 0–100%
scale based on the difference between the background OD and
the maximum OD in each animal. The six perivascular OD
values were typically similar, and were averaged to obtain a
representative value for fluorescein leakage in the pial venular
network for each animal.
Statistical Analysis
Sample sizes were determined based on data obtained in a
previous publication (32), using a power of 0.80 and an alpha
value of 0.05. Sample sizes were determined to be n= 5 per group.
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TABLE 1 | Values are means ± S.E.M. Baseline values reported are averaged from two measurements recorded 30min apart.
Time point Control Asphyxia (+) Asphyxia (−) Asphyxia +
SOD
Asphyxia +
C3
Asphyxia +
Oxypurinol (5 mg/kg)
Asphyxia + Oxypurinol (50
mg/kg)
MEAN ARTERIAL BLOOD PRESSURE (mm Hg)
Baseline 56 ± 1 57 ± 2 59 ± 1 55 ± 1 54 ± 1 55 ± 2 56 ± 1
1 h 55 ± 1 54 ± 2 58 ± 1 53 ± 1 51 ± 1 54 ± 2 55 ± 1
2 h 56 ± 1 52 ± 2 55 ± 1# 53 ± 0 52 ± 2 51 ± 1 54 ± 1
BLOOD GLUCOSE (mg/dL)
Baseline 88 ± 7 104 ± 6 103 ± 5 95 ± 5 126 ± 3* 111 ± 22 91 ± 4
1 h 92 ± 7 120 ± 5* 117 ± 10 106 ± 8 135 ± 8* 112 ± 12 109 ± 10
2 h 93 ± 7 122 ± 6 107 ± 10 93 ± 10 124 ± 15 88 ± 10 89 ± 8
ARTERIAL pH
Baseline 7.38 ± 0.01 7.36 ± 0.01 7.38 ± 0.01 7.34 ± 0.02 7.34 ± 0.02 7.41 ± 0.02 7.37 ± 0.02
1 h 7.36 ± 0.01 7.31 ± 0.02 7.32 ± 0.02 7.29 ± 0.02 7.29 ± 0.01 7.35 ± 0.02 7.33 ± 0.02
2 h 7.35 ± 0.01 7.35 ± 0.02 7.34 ± 0.02 7.33 ± 0.02 7.34 ± 0.02 7.40 ± 0.01 7.36 ± 0.01
ARTERIAL PARTIAL PRESSURE OF CO2 (mm Hg)
Baseline 40 ± 1 38 ± 1 38 ± 1 38 ± 1 43 ± 1 37 ± 1 37 ± 2
1 h 41 ± 1 38 ± 2 40 ± 1 39 ± 1 41 ± 3 37 ± 2 40 ± 2
2 h 40 ± 1 35 ± 1 39 ± 1 39 ± 2 41 ± 2 36 ± 2 38 ± 3
ARTERIAL PARTIAL PRESSURE OF O2 (mm Hg)
Baseline 94 ± 3 98 ± 3 95 ± 2 94 ± 3 88 ± 2 96 ± 3 91 ± 2
1 h 96 ± 2 101 ± 3 105 ± 4 103 ± 4 98 ± 4 93 ± 3 102 ± 4
2 h 92 ± 2 105 ± 4 100 ± 2 94 ± 2 112 ± 11* 94 ± 3 99 ± 4
(+), with aCSF superfusion across the cranial window; (−), without aCSF superfusion across the cranial window. *p < 0.05 vs. control at the same time point; #p < 0.05 vs. baseline
mean arterial blood pressure value for asphyxia without aCSF superfusion.
Since a limited number of animals could be studied in 1 day and
control and asphyxia animals were included with every drug-
treated group, control and asphyxia groups have larger sample
sizes than drug-treated groups.
All statistics were performed using SigmaStat 4.0. One-
way analysis of variance (ANOVA) and Tukey tests were
performed for data shown in Table 1 and for Figures 2B,C.
Two-way repeated measures ANOVA and Holm-Sidak tests were
performed for Figures 1B,C. A Shapiro-Wilk test was performed
and a Spearman’s rank correlation coefficient was determined for
Figure 2D. Significant differences were noted if p < 0.05.
RESULTS
Mean arterial blood pressure, blood glucose, arterial pH, arterial
partial pressure of CO2, and arterial partial pressure of O2
at baseline and at 1 and 2 h of reperfusion are displayed in
Table 1. Significant differences within and between groups are
displayed in Table 1. While measures of blood glucose at 2 h,
arterial pH at 1 h, and arterial partial pressure of CO2 at
baseline and at 2 h demonstrated significant differences between
the control, asphyxia with aCSF superfusion, asphyxia with
SOD, and asphyxia with C3 groups overall (p < 0.05), post-hoc
analyses revealed no individual between-group differences that
were significant. No significant differences existed between the
asphyxia groups and any of the corresponding treatment groups
for any of the parameters at any time point.
Relative to non-asphyxial control animals, asphyxia
resulted in progressive increases in the number of leukocytes
adherent to cerebral venules during the initial 2 h of
reperfusion (Figures 1A–C), consistent with our earlier
studies (32, 34, 36). Adherence was 62% greater at 1 h
and 23% greater at 2 h in asphyxial animals in which the
window was superfused with aCSF (Figure 1B) relative to
asphyxial animals in which the aCSF remained static during the
experiment (Figure 1C).
After 2 h of post-asphyxial reperfusion, significant increases
in sodium fluorescein permeability were also observed relative
to non-asphyxial control animals (Figures 2A–C), indicative of a
compromised BBB (32, 34, 36). In particular, in asphyxial animals
with aCSF window superfusion, permeability was increased 42
± 3% (Figure 2B), whereas in asphyxial animals with static
aCSF under the window, permeability increased less (29 ± 3%;
Figure 2C).
To determine if O
·
2 participated in promoting the elevated
leukocyte adherence and/or the loss of BBB integrity that
characterized the acute inflammatory response to asphyxia, we
assessed the effects of removing O
·
2 by the extracellularly-
confined enzyme SOD or by C3 (30). Topical superfusion of
SOD significantly reduced leukocyte adherence at 1 and 2 h of
reperfusion in asphyxial animals (Figure 1B). SOD also reduced
asphyxia-induced elevations in BBB permeability to fluorescein
(Figure 2B). Topical superfusion of C3 also reduced the post-
asphyxial inflammatory response. As shown in Figures 1A,B and
2A,B, respectively, asphyxia-induced increases in both leukocyte
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FIGURE 1 | SOD, the SOD mimetic C3, and oxypurinol block the asphyxia-mediated increase in leukocyte adherence. (A) Representative images of rhodamine
6G-labeled adherent leukocytes in control animals, asphyxial animals, and asphyxial animals administered C3, at 2 h of reperfusion. (B) Animals induced with asphyxia
and concomitant window superfusion with aCSF (n = 14) exhibited a statistically significant increase in leukocyte adherence relative to control animals (n = 13) at both
1 and 2 h of reperfusion. Animals continuously administered 1,000 U/ml SOD at a rate of 50 µl/min by window superfusion beginning 30min prior to asphyxia (n = 9)
exhibited significantly decreased leukocyte adherence relative to asphyxial animals at both 1 and 2 h of reperfusion. Animals continuously administered 300µM C3 at
a rate of 50 µl/min by window superfusion beginning 30min prior to asphyxia (n = 5) exhibited significantly decreased leukocyte adherence relative to asphyxial
animals at 2 h of reperfusion. (C) Animals induced with asphyxia without aCSF superfusion across the window (n = 8) had a statistically significant increase in
leukocyte adherence relative to control animals (n = 13) at both 1 and 2 h of reperfusion. Animals administered 50 mg/kg oxypurinol 30min prior to undergoing the
asphyxia protocol (n = 6) exhibited significantly decreased leukocyte adherence relative to asphyxial animals at both 1 and 2 h of reperfusion. Animals administered 5
mg/kg oxypurinol 30min prior to undergoing the asphyxia protocol (n = 6) exhibited no change in leukocyte adherence relative to asphyxial animals at either time
point. Values shown (mean ± S.E.M.) represent increases above baseline in the number of leukocytes adherent to cerebral venules after 1 and 2 h of post-asphyxial
reperfusion. *p < 0.05 vs. control; #p < 0.05 vs. asphyxia.
adherence and BBB permeability were significantly attenuated by
this O
·
2 scavenger.
We tested the hypothesis that xanthine oxidase is one
source of O
·
2 following asphyxia by assessing the effects
of oxypurinol on asphyxia-induced increases in leukocyte
adherence and BBB permeability. Inhibition of endothelial
and circulating xanthine oxidase activity with intravenous
administration of oxypurinol significantly and dose-dependently
reduced asphyxia-induced leukocyte adherence to post-
capillary venules to levels that, at the higher dose, were
not different from non-asphyxial controls (Figure 1C).
Similarly, reductions in asphyxia-induced BBB breakdown
were evidenced after administration of the higher dose of
oxypurinol (Figure 2C).
When all experimental conditions were examined collectively,
changes in leukocyte-endothelial adherence were highly
correlated to changes in fluorescein permeability (r2 = 0.92;
Figure 2D), suggesting a causal relationship between leukocyte
adherence and BBB integrity.
DISCUSSION
We demonstrated a marked, time-dependent increase in
leukocyte adherence to cerebral venules and a loss in BBB
integrity during the initial 2 h of reperfusion following asphyxia.
Local superoxide scavenging with C3 or SOD, or systemic
inhibition of xanthine oxidase activity with oxypurinol,
significantly decreased these inflammatory responses. These
results suggest that the formation of inflammation-promoting
concentrations of O
·
2 results in part from the breakdown of high
energy adenine nucleotides and the resulting elevation in purine
catabolites, which in turn serve as substrates for endothelial and
circulating xanthine oxidase.
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FIGURE 2 | SOD, C3, and oxypurinol block the asphyxia-mediated increases in vascular fluorescein permeability, and vascular fluorescein permeability directly
correlates with leukocyte adherence. (A) Representative images of sodium fluorescein permeability in control animals, asphyxial animals, and asphyxial animals
administered C3, at 2 h of post-asphyxial reperfusion and 20min after fluorescein administration. Raw images were used for all data analyses, but for publication clarity,
images had brightness and contrast enhanced (all images modified equally). (B) Animals induced with asphyxia and concomitant cranial window superfusion with
aCSF (NT; n = 8) exhibited a statistically significant increase in vascular fluorescein permeability relative to control animals (n = 13). Animals continuously administered
1,000 U/ml SOD at a rate of 50 µl/min by window superfusion (n = 7) exhibited significantly decreased vascular fluorescein permeability relative to asphyxial animals.
Similarly, animals continuously administered 300µM C3 at a rate of 50 µl/min by window superfusion (n = 5) exhibited significantly decreased vascular fluorescein
permeability relative to asphyxial animals. (C) Animals induced with asphyxia without aCSF superfusion across the cranial window (NT; n = 11) exhibited a statistically
significant increase in vascular fluorescein permeability relative to control animals (n = 13). Animals administered 50 mg/kg oxypurinol (n = 6) exhibited significantly
decreased vascular fluorescein permeability relative to asphyxial animals. Animals administered 5 mg/kg oxypurinol (n = 6) exhibited no change in vascular fluorescein
permeability relative to asphyxial animals. (D) A linear regression was generated by matching leukocyte adherence to the corresponding vascular fluorescein
permeability under the different experimental conditions. Values shown (mean ± S.E.M.) represent the percent increase in optical density relative to that measured
before fluorescein administration. NT, not treated; (+), with aCSF superfusion; (–), without aCSF superfusion. *p < 0.05 vs. control; #p < 0.05 vs. asphyxia.
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Numerous studies in the brain have demonstrated that
oxygen free radicals are produced upon reperfusion following
ischemia, and that their generation through various biochemical
pathways during reperfusion is associated with increases in
BBB permeability (37). The significant reduction in leukocyte
adherence observed when animals were administered C3 or
SOD indicates that O
·
2, generated from circulating neutrophils
(38), cerebrovascular endothelial and smooth muscle cells (39),
and/or the parenchyma surrounding the vasculature (38, 40–42),
contributes to this vascular inflammatory response to asphyxia.
The increase in BBB permeability following asphyxia is reduced
by C3 or SOD treatment, which parallels the reduction in
leukocyte adherence in asphyxial animals treated with either of
these drugs. This is consistent with the notion that leukocyte
adherence is a cause of BBB breakdown, at least in the acute
post-asphyxial setting (43). Moreover, consistent with clinical
studies of allopurinol in neonatal asphyxia (44), our results
suggest that xanthine oxidase is a major source of O
·
2 produced
in response to asphyxia, given that oxypurinol also significantly
reduced asphyxia-mediated increases in leukocyte adherence and
BBB permeability. The extent to which the latter inflammatory
events result from oxypurinol-induced reductions in superoxide
production and/or oxypurinol-induced increases in adenosine
cannot be ascertained from the results of our study.
While all experimental treatments in this study were
effective in reducing leukocyte adherence and BBB permeability,
neither oxypurinol nor SOD is an ideal therapeutic compound.
Oxypurinol first needs to be converted to an active state, and its
potency is weak. SOD may lack substantial brain uptake due to
its relatively large size. On the other hand, C3 has several features
which may prove attractive clinically. It acts catalytically (27),
and therefore retains activity for as long as it is present, has a
plasma half-life of 8 h, and demonstrates significant brain uptake
in both rodents and non-human primates (29, 45). C3 is also
highly water soluble and has oral bioavailability (45). While C3
is roughly 100-fold less active than SOD itself (27), its ability to
access mitochondria as well as other intracellular compartments
may enhance its overall biological efficacy, especially as it appears
to have a good safety profile with long-term (2 years, mice;
2 months, primates) chronic administration (19, 45). Newborn
infants could theoretically be treated with C3 via oral fluids such
as formula, or intravenously. Future investigation could help
define the time window during which compounds such as C3 are
effective in reducing the deleterious effects of neonatal asphyxia.
In this proof-of-concept study, we administered the
superoxide scavenging agents C3 and SOD locally via cranial
window superfusion, and the xanthine oxidase inhibitor
oxypurinol systemically, 30min prior to asphyxia, with the
pharmacokinetics-based intention of providing some time for
these agents to reach the intracellular and intercellular locations
where superoxide might be generated rapidly during or shortly
after asphyxia; whether their efficacy would have been as robust
when administered after asphyxia, to more closely mimic the
clinical situation, is unclear. We also did not explore the effects
of oral or systemic C3 on post-asphyxial inflammation, as this
would have involved dose-finding experiments requiring more
C3 than was available. In addition, we focused on the acute
response to asphyxia and did not attempt to quantify the extent
of leukocyte diapedesis into brain parenchyma, nor measure
endpoints, such as CA1 pyramidal neuron death, that are more
indicative of asphyxial brain injury and the potential long-term
neuroprotective effects of our interventions. Finally, while we
found strong correlations between the extent of post-asphyxial
leukocyte adherence to the venular endothelium and BBB
breakdown under control conditions and in response to our
interventions, we cannot conclude with certainty that the former
caused 100% of the latter. It is possible that O
·
2 contributed
to some portion of the observed BBB breakdown, not only
independent of the extent of leukocyte adherence to the venular
endothelium, but to BBB breakdown in other parts of the
microvasculature as well.
In summary, we found that O
·
2 is produced in response to
asphyxia, that xanthine oxidase is an important enzymatic source
of this radical, and that scavenging of O
·
2 by administering C3
or SOD, or preventing its formation, can ameliorate this acute
inflammatory response and lessen its potential to damage the
neonatal cerebral microcirculation.
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